Separate calculation of DW-MRI in assessing therapeutic effect in liver tumors in rats

World Journal of Gastroenterology

Volumn 19, Issue 47, 2013, Pages 9092-9103

  Chen, Feng ^a,b   De Keyzer, Frederik ^b   Feng, Yuan Bo ^b   Cona, Marlein Miranda ^b   Yu, Jie ^b   Marchal, Guy ^b   Oyen, Raymond ^b   Ni, Yi Cheng ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Animal model; Antiangiogenic agent; Diffusion weighted imaging; Liver tumor; Magnetic resonance imaging; Rats; Rodents; Therapeutic assessment; Vascular disrupting agent

Indexed keywords

N ACETYLCOLCHINOL PHOSPHATE; THALIDOMIDE; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; HISTOLOGY; HISTOPATHOLOGY; LIVER TUMOR; NONHUMAN; RAT; TUMOR GROWTH; TUMOR VOLUME;

ANIMAL MODEL; ANTIANGIOGENIC AGENT; DIFFUSION WEIGHTED IMAGING; LIVER TUMOR; MAGNETIC RESONANCE IMAGING; RATS; RODENTS; THERAPEUTIC ASSESSMENT; VASCULAR DISRUPTING AGENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIFFUSION MAGNETIC RESONANCE IMAGING; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; NECROSIS; ORGANOPHOSPHORUS COMPOUNDS; PREDICTIVE VALUE OF TESTS; RATS; RHABDOMYOSARCOMA; THALIDOMIDE; TIME FACTORS; TUMOR BURDEN;

EID: 84890937043     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i47.9092     Document Type: Article

References (29)

1. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57: 1829-1834 [PMID: 9157969]
2. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5: 423-435 [PMID: 15928673 DOI: 10.1038/nrc1628]
3. Kanthou C, Tozer GM. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 2009; 90: 284-294 [PMID: 19563611 DOI: 10.1111/j.1365-2613.2009.00651.x]
4. Siemann DW. The unique characteristics of tumor vascula-ture and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 2011; 37: 63-74 [PMID: 20570444 DOI: 10.1016/j.ctrv.2010.05.001]
5. Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology 2010; 256: 348-364 [PMID: 20656830 DOI: 10.1148/radiol.10091760]
6. Thoeny HC, De Keyzer F, Chen F, Vandecaveye V, Verbek-en EK, Ahmed B, Sun X, Ni Y, Bosmans H, Hermans R, van Oosterom A, Marchal G, Landuyt W. Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia 2005; 7: 779-787 [PMID: 16207480 DOI: 10.1593/neo.04748]
7. Thoeny HC, De Keyzer F, Vandecaveye V, Chen F, Sun X, Bosmans H, Hermans R, Verbeken EK, Boesch C, Marchal G, Landuyt W, Ni Y. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 2005; 237: 492-499 [PMID: 16192323 DOI: 10.1148/radiol.2372041638]
8. Thoeny HC, De Keyzer F, Chen F, Ni Y, Landuyt W, Ver-beken EK, Bosmans H, Marchal G, Hermans R. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 2005; 234: 756-764 [PMID: 15734932 DOI: 10.1148/radi-ol.2343031721]
9. Sun X, Wang H, Chen F, De Keyzer F, Yu J, Jiang Y, Feng Y, Li J, Marchal G, Ni Y. Diffusion-weighted MRI of hepatic tumor in rats: comparison between in vivo and postmortem imaging acquisitions. J Magn Reson Imaging 2009; 29: 621-628 [PMID: 19243058 DOI: 10.1002/jmri.21675]
10. Chandarana H, Lee VS, Hecht E, Taouli B, Sigmund EE. Comparison of biexponential and monoexponential model of diffusion weighted imaging in evaluation of renal lesions: preliminary experience. Invest Radiol 2011; 46: 285-291 [PMID: 21102345]
11. Yamada I, Aung W, Himeno Y, Nakagawa T, Shibuya H. Diffusion coeffcients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 1999; 210: 617-623 [PMID: 10207458]
12. Kivivuori SM, Riikonen P, Valanne L, Lönnqvist T, Saarin-en-Pihkala UM. Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem glio-mas. Acta Paediatr 2011; 100: 134-138 [PMID: 20712831 DOI: 10.1111/j.1651-2227.2010.01961.x]
13. Chen F, Sun X, De Keyzer F, Yu J, Peeters R, Coudyzer W, Vandecaveye V, Landuyt W, Bosmans H, Van Hecke P, Marchal G, Ni Y. Liver tumor model with implanted rhab-domyosarcoma in rats: MR imaging, microangiography, and histopathologic analysis. Radiology 2006; 239: 554-562 [PMID: 16543589 DOI: 10.1148/radiol.2392050277]
14. Chen F, De Keyzer F, Wang H, Vandecaveye V, Landuyt W, Bosmans H, Hermans R, Marchal G, Ni Y. Diffusion weighted imaging in small rodents using clinical MRI scanners. Methods 2007; 43: 12-20 [PMID: 17720559 DOI: 10.1016/ j.ymeth.2007.03.007]
15. Koh DM, Collins DJ, Orton MR. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol 2011; 196: 1351-1361 [PMID: 21606299 DOI: 10.2214/AJR.10.5515]
16. van Heeckeren WJ, Sanborn SL, Narayan A, Cooney MM, McCrae KR, Schmaier AH, Remick SC. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol 2007; 14: 468-480 [PMID: 17934353 DOI: 10.1097/ MOH.0b013e3282a6457f]
17. Reck M, Gatzemeier U. Targeted therapies: Thalidomide in lung cancer therapy-what have we learned? Nat Rev Clin Oncol 2010; 7: 134-135 [PMID: 20190796 DOI: 10.1038/nrcli-nonc.2010.11]
18. Wang H, Sun X, Chen F, De Keyzer F, Yu J, Landuyt W, Vandecaveye V, Peeters R, Bosmans H, Hermans R, Marchal G, Ni Y. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol 2009; 44: 44-53 [PMID: 19034028 DOI: 10.1097/RLI.0b013e31818e5ace]
19. Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int 2007; 99: 1047-1055 [PMID: 17437439 DOI: 10.1111/j.1464-410X.2007.06763.x]
20. Chen F, Feng Y, Zheng K, De Keyzer F, Li J, Feng Y, Cona MM, Wang H, Jiang Y, Yu J, Marchal G, Verfaillie C, De Geest B, Oyen R, Ni Y. Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparamet-ric MRI. PLoS One 2012; 7: e41140 [PMID: 22815943 DOI: 10.1371/journal.pone.0041140]
21. Stewart EE, Sun H, Chen X, Schafer PH, Chen Y, Garcia BM, Lee TY. Effect of an angiogenesis inhibitor on hepatic tumor perfusion and the implications for adjuvant cytotoxic therapy. Radiology 2012; 264: 68-77 [PMID: 22627603 DOI: 10.1148/radiol.12110674]
22. Wang H, Li J, Chen F, De Keyzer F, Yu J, Feng Y, Nuyts J, Marchal G, Ni Y. Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours. Eur Radiol 2010; 20: 2013-2026 [PMID: 20182730 DOI: 10.1007/s00330-010-1743-5]
23. Rheinheimer S, Stieltjes B, Schneider F, Simon D, Pahernik S, Kauczor HU, Hallscheidt P. Investigation of renal lesions by diffusion-weighted magnetic resonance imaging applying intravoxel incoherent motion-derived parameters-initial experience. Eur J Radiol 2012; 81: e310-e316 [PMID: 22104090 DOI: 10.1016/j.ejrad.2011.10.016]
24. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986; 161: 401-407 [PMID: 3763909]
25. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168: 497-505 [PMID: 3393671]
26. Le Bihan D. Intravoxel incoherent motion perfusion MR imaging: a wake-up call. Radiology 2008; 249: 748-752 [PMID: 19011179 DOI: 10.1148/radiol.2493081301]
27. Takahara T, Kwee TC. Low b-value diffusion-weighted imaging: emerging applications in the body. J Magn Reson Imaging 2012; 35: 1266-1273 [PMID: 22359279 DOI: 10.1002/ jmri.22857]
28. Guiu B, Petit JM, Capitan V, Aho S, Masson D, Lefevre PH, Favelier S, Loffroy R, Vergès B, Hillon P, Krausé D, Cercueil JP. Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver disease: a 3.0-T MR study. Radiology 2012; 265: 96-103 [PMID: 22843768 DOI: 10.1148/ radiol.12112478]
29. Pang Y, Turkbey B, Bernardo M, Kruecker J, Kadoury S, Merino MJ, Wood BJ, Pinto PA, Choyke PL. Intravoxel incoherent motion MR imaging for prostate cancer: an evaluation of perfusion fraction and diffusion coeffcient derived from different b-value combinations. Magn Reson Med 2013; 69: 553-562 [PMID: 22488794]